MIST Share Price Performance
US$1.51
0.10 (7.09%)
Price US$1.51
Share PriceUS$1.51
MIST Community Narratives
There are no narratives available yet.
Recent MIST News & Updates
No updates
Milestone Pharmaceuticals Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.53
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -886.6%
Milestone Pharmaceuticals Inc. Competitors
About MIST
- Founded
- 2003
- Employees
- 33
- CEO
- WebsiteView website
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Canadian Market Performance
- 7 Days: 0.4%
- 3 Months: 7.1%
- 1 Year: 21.0%
- Year to Date: 9.9%
In the last week, the market has stayed flat, however the Materials sector stood out, gaining 6.6%. More promisingly, the market is up 21% over the past year. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading